Northern Trust Corp Codiak Bio Sciences, Inc. Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.24 - $6.96 $250,741 - $779,088	-111,938 Reduced 81.07%	26,131 $75,000
Q1 2022 May 13, 2022	SELL	$4.3 - $12.95 $26,316 - $79,254	-6,120 Reduced 4.24%	138,069 $866,000
Q4 2021 Feb 08, 2022	BUY	$10.0 - $16.78 $41,430 - $69,519	4,143 Added 2.96%	144,189 $1.61 Million
Q3 2021 Nov 15, 2021	SELL	$15.58 - $22.88 $28,355 - $41,641	-1,820 Reduced 1.28%	140,046 $2.29 Million
Q2 2021 Aug 13, 2021	BUY	$11.72 - $26.81 $797,674 - $1.82 Million	68,061 Added 92.22%	141,866 $2.63 Million
Q1 2021 May 12, 2021	BUY	$13.49 - $31.53 $131,891 - $308,268	9,777 Added 15.27%	73,805 $1.11 Million
Q4 2020 Feb 11, 2021	BUY	$7.9 - $32.3 $505,821 - $2.07 Million	64,028 New	64,028 $2.07 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.